[ad_1]
Come back Wednesday 28 September, at 6.30pmCantiere Futuro, the event organized by the Chamber of Commerce of Milan, Monza, Brianza and Lodi in partnership with Wired. For the third appointment of the review, also at Palazzo Giureconsulti, a stone’s throw from the Milan cathedral, the focus will be onInternational Medtech. On stage, industry players such as Pierluigi Paracchico-founder of Genenta Science, Elena BeltramiBiotech Venture Advisor, Matteo CresciniCEO of WsN4Life, e Paola OchettaCEO and co-founder of BiomimX.
The union between medicine and technology has opened the door to a new era of science, also focused on data analysis, predictive diagnostics and gene therapy. Thanks to scientific research and technology transfer, innovative solutions for the treatment of diseases now considered invincible and new therapies to accelerate traditional treatment processes are studied with the ideas brought from the laboratory to the market. A frontier crossed every day thanks to the work of researchers.
How much is Medtech worth in the world
The anti-Covid mRNA vaccines, created thanks to years of research by two old biotech startups, such as Moderna and Biontech, have demonstrated the full power of technology applied in the medical field. But they are by no means the only stars in the industry. A search by Mediobanca has lined up numbers to understand the economic power of Medtech: in 2021 the sector had a worldwide turnover of 535.6 billion euros and forecasts for 2024 they are 632.6 billion in revenues. Medtech is already worth 5.5% of world health spending and develops investments in research for 33 billion euros.
In Europe, Medtech boasts a turnover of 155 billion euros and according to Mediobanca estimates 12% moves to Italy: “In 2020, the aggregate turnover of the 227 main companies of the Italian Medtech amounted to 18.6 billion eurosof which 8.9 billion from production companies and 9.7 billion from commercial ones “we read in the analysis by Piazzetta Cuccia. “In the two-year period 2018-2020, the Italian Medtech achieved an average annual growth of 7%, with the foreign turnover (+ 9%) which ran more than the national one (+ 5.7%)”with the prospects for 2022 that are underway “Very positive”.
Who are the protagonists of Future construction site
Cantiere Futuro sul Medtech will open with an interview with the director of WiredFederico Ferrazza, to Piergluigi Paracchi who founded Genenta Science with Luigi Naldini, bringing the idea from the laboratories of San Raffaele di Milano until the listing in the United States of America (first Italian company ever on Nasdaq). Then space for Elena Beltrami who, after a PhD in Pharmacological Sciences, worked for almost a decade at the Telethon Foundation to devote herself to tech transfer before becoming Biotech Venture Advisor. Beltrami will talk about future prospects in the sector with Paola Ochetta, CEO of the precision medicine startup BiomimX, and with Matteo Crescini, CEO of WsN4Life, a clinical engineering company in Monza that produces medical devices for patients with chronic diseases.
.
[ad_2]
Source link
